Advanced in Chondrosarcoma

Yasuhito U. Tanaka

Kumamoto, JP 
Advanced in Chondrosarcoma
Kumamoto, JP 
OverviewLocationsClinical Research

Overview

Yasuhito Tanaka practices in Kumamoto, Japan. Tanaka is rated as an Advanced expert by MediFind in the treatment of Chondrosarcoma. Their top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, Osteotomy, and Endoscopy.

Their clinical research consists of co-authoring 895 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Chondrosarcoma.

Locations

Kumamoto, Japan
Other Locations
Nara-shi, Japan
Nagoya, Japan
Kashihara-shi, 6348521, Japan
Yao, Japan
Kashihara, 6348521, Japan
Chuo, 8608556, Japan
Yamanashi, Japan
Kurume, Japan
Honjo, 8608556, Japan
Koyodai, 5840082, Japan
Kashiba, Japan
Isehara, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drugs: GSK3228836, PegIFN, NA therapy
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

893 Total Publications

Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.
Journal: medRxiv : the preprint server for health sciences
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tanaka's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 100 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile